(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.57%) $79.71
(1.09%) $2.33
(0.71%) $2 357.00
(0.69%) $28.56
(0.41%) $994.90
(0.04%) $0.928
(-0.15%) $10.85
(0.02%) $0.799
(0.02%) $92.56
4 days till quarter result
(bmo 2024-05-14)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform...
Stats | |
---|---|
本日の出来高 | 226 369 |
平均出来高 | 803 516 |
時価総額 | 251.33M |
EPS | $0 ( 2024-03-26 ) |
次の収益日 | ( $-0.890 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.97 |
ATR14 | $0.0540 (0.66%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-17 | Miller Mary | Sell | 558 | Common Stock |
2024-04-11 | Ra Capital Management, L.p. | Buy | 3 530 000 | Common Stock |
2024-04-11 | Perceptive Advisors Llc | Buy | 2 353 000 | Common Stock |
2024-03-04 | Palani Santhosh | Buy | 32 500 | Stock Option (Right to Buy) |
2024-03-04 | Palani Santhosh | Buy | 0 |
INSIDER POWER |
---|
24.86 |
Last 56 transactions |
Buy: 13 025 326 | Sell: 16 556 327 |
ボリューム 相関
Acrivon Therapeutics, 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Acrivon Therapeutics, 相関 - 通貨/商品
Acrivon Therapeutics, 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-536 000 (0.00 %) |
EPS: | $-2.74 |
FY | 2023 |
収益: | $0 |
総利益: | $-536 000 (0.00 %) |
EPS: | $-2.74 |
FY | 2022 |
収益: | $0 |
総利益: | $-1.10M (0.00 %) |
EPS: | $-1.350 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.260 |
Financial Reports:
No articles found.
Acrivon Therapeutics,
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。